BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026)
BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 1,036.00 |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 175.00 |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 120.00 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 434.00 |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | -295.00 |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 1,076.00 |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | 1,898.00 |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.40 Mn | 24.40 Mn | 160,000.00 | 19,844.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19,844.00 |
| Mar 31, 2026 | 43,509.00 |
| Dec 31, 2025 | 63,919.00 |
| Sep 30, 2025 | 207,555.00 |
| Jun 30, 2025 | 437,439.00 |
| Mar 31, 2025 | -35,852.00 |
| Dec 31, 2024 | -26,874.00 |
| Sep 30, 2024 | -20,273.00 |
| Jun 30, 2024 | -19,157.00 |
| Mar 31, 2024 | -26,373.00 |
| Dec 31, 2023 | -24,939.00 |
| Sep 30, 2023 | -20,292.00 |
| Jun 30, 2023 | -6,886.00 |
| Mar 31, 2023 | -2,491.00 |
| Dec 31, 2022 | 2,345.00 |
| Sep 30, 2022 | 4,603.00 |
| Jun 30, 2022 | 3,966.00 |
| Mar 31, 2022 | 1,220.00 |
| Dec 31, 2021 | 288.00 |
| Sep 30, 2021 | -776.00 |